Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aligos Therapeutics

< Previous 1 2 3 Next >
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Positive Data at APASL 2025
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces $105 Million Private Placement Financing
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Present at Investor Conferences in December
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Present at Investor Conferences in October
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS HAE NVO PLRX
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Reverse Stock Split
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Strengthens Board with Two New Independent Directors
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.